Publications
Download as DOCX, PDF0 likes52 views
This document lists publications by Dr. Campbell and others related to multiple sclerosis (MS) research. It includes peer-reviewed journal articles on topics like determinants of adherence to MS therapies, effects of comorbidities on treatment, drug-induced liver injury from interferon beta, and genetic risk factors for pediatric MS. It also lists several review articles and book chapters authored by Dr. Campbell on MS management and therapies.
More Related Content
What's hot (17)
Similar to Publications (20)
Publications
- 1. Publications McKay KA, Tremlett H, Patten SB, Fisk JD, Evans C, Fiest K, Campbell T, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS). Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross- Canada prospective study. Mult Scler. 2016 Jun 29. Zhang T, Tremlett H, Leung S, Zhu F, Kingwell E, Fisk JD, Bhan V, Campbell TL, Stadnyk K, Yu BN, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology. 2016 Mar 4. Kowalec K, Kingwell E, Yoshida EM, Marrie RA, Kremenchutzky M, Campbell TL, Wadelius M, Carleton B, Tremlett H. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opin Drug Saf. 2014 Oct;13(10):1305-17. doi: 10.1517/14740338.2014.947958. Epub 2014 Aug 18. Wong, S., Migounov, V., Campbell, TL., Morreale, M., Cass, E. Avonex PEN Satisfaction and Patients Experience Clinical Trial. Canadian Journal of Neurological Sciences. November, 2013 40(6); 898-99. Campbell, T Combining Physical Therapy with Dalfampridine in Patients with Multiple Sclerosis and Walking Limitations, Consortium of Multiple Sclerosis Centers Newsletter Issue 1, Orlando, Florida, USA, May 2013 – REVIEW ARTICLE Campbell, T Prospective, Longitudinal Study of Natalizumab Treatment in MS Patients, Consortium or Multiple Sclerosis Centers Newsletter Issue 2, Orlando, Florida, USA, May 2013 – REVIEW ARTICLE. Campbell,T. Tysabri Patient Management Recommendations, Canadian Nursing Academy in Multiple Sclerosis, April 2013 Disanto G1, Magalhaes S, Handel AE, Morrison KM, Sadovnick AD, Ebers GC, Banwell B, Bar- Or A; Canadian Pediatric Demyelinating Disease Network (including Campbell, TL). HLA- DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination. Neurology. 2011 Mar 1;76(9):781-6. Venkateswaran S, Zheng K, Sacchetti M, Gagne D, Arnold DL, Sadovnick AD, Scherer SW, Banwell B, Bar-Or A, Simon DK; Canadian Pediatric Demyelinating Disease Network (including Campbell, TL). Mitochondrial DNA haplogroups and mutations in children with acquired central demyelination. Neurology. 2011 Mar 1;76(9):774-80. Campbell, T. Multiple Sclerosis: A guide for health care professionals. Multiple Sclerosis Society of Canada Alberta Division, 2010.
- 2. Poder, K., Ghatavi, K., Fisk, J.D., Campbell, T.L., Kisley, S., Sarty, I., Stadnyk, K., Bhan, V., Social anxiety in a multiple sclerosis clinic population. Multiple Sclerosis 2009; 15; 393-398. Hebb, A.L.O., Moore, C.S., Bhan, V., Campbell, T., Fisk, J.D., Robertson, H.A., Thorne, M., Lacasse, E., Holcik, M., Gillard, J., Crocker, S. J., Robertson, G. S. Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. Multiple Sclerosis 2008: 14; 577-594. Campbell, T. (2007). Highlights from the 20th Annual Meeting of the Consortium of MS Centers (CMSC), Compass, 8(1), 10-11. Campbell, T. (2007). Therapies targeting T and B cells, issues in placebo-controlled trails, neutralizing antibodies, quantifying MS costs….. Highlights from the 20th Annual Meeting of the Consortium of MS Centers (CMSC), Neurotransmission, 8(1), 9. Campbell, T. (2007). Highlights from the 20th Annual Meeting of the Consortium of MS Centers (CMSC), held May 31 to June 3, 2006 in Scottsdale, Arizona. Compass, 8(1), 10-11. Campbell, T. (2007). Therapies targeting T and B cells, issues in placebo-controlled trails, neutralizing antibodies, quantifying MS costs….. Highlights from the 20th Annual Meeting of the Consortium of MS Centers (CMSC), held May 31 to June 3, 2006 in Scottsdale, Arizona. Neurotransmission, 8(1), 9. Campbell, T. L. (2004). You’ve just found out that you have multiple sclerosis …now what? Unrestricted Educational Grant, Biogen Idec Canada Inc Lanigan, T. L. (2000). The patient family learning centre. The Canadian Nurse, 96(3), 18-22 Lanigan, T. L. (1998). Project Manual Section 1: Stress Management. Prince Edward Island Hearth Health Program and Healthy Communities in Action Population Health Fund. Charlottetown, Prince Edward Island, Canada